Ratings Novavax, Inc.

Equities

NVAX

US6700024010

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-05 pm EDT			5-day change	1st Jan Change
20.97 ^USD	+18.27%		+38.78%	+336.88%

Jun. 05	Novavax Says It Can Deliver Recommended Covid Vaccine in September	DJ
Jun. 05	COVID shots for JN.1 variant neutralize newer strains, vaccine makers say	RE

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Analyst opinion has improved significantly over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company's enterprise value to sales, at 2.14 times its current sales, is high.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
NOVAVAX, INC.	+336.88%	2.94B	C-
MODERNA, INC.	+55.70%	59.34B	B-
LONZA GROUP AG	+41.08%	40.24B	A
IQVIA HOLDINGS INC.	-5.39%	39.88B	B
CELLTRION, INC.	-5.56%	28.55B	C
ICON PUBLIC LIMITED COMPANY	+16.46%	27.26B	B-
ALNYLAM PHARMACEUTICALS, INC.	-20.56%	19.23B	B
MEDPACE HOLDINGS, INC.	+33.03%	12.61B	C+
UNITED THERAPEUTICS CORPORATION	+25.85%	12.28B	B+
BIO-TECHNE CORPORATION	+2.72%	12.49B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes